Acura extends loan maturity and NDA deadline with AD Pharma, warns of possible shutdown

ACURA PHARMACEUTICALS, INC

Received $200,000 loan from AD Pharma on June 24, 2026, bringing principal balance to $10,694,279 with accrued interest of ~$1.16M.
Extended NDA acceptance deadline for LTX-03 from June 30, 2026 to December 31, 2026 via amendment #14 to license agreement.
Extended maturity date of secured promissory note from June 30, 2026 to December 31, 2026 via amendment #8.
Extended warrant expiration date to December 31, 2026 and noted AD Pharma owns ~65% of outstanding common stock.
Warns that without additional financing by late July 2026, may need to scale back operations, furlough employees, or seek bankruptcy protection.

Featured in Daily 8-K Digest

Selected #5 for 2026-06-29. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.